MIMI KINGERY: Open Payments
NPI 1790065035 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,123 in 85 payments from 16 companies in 2025. Trend: 2023 $1,835 · 2024 $1,846 · 2025 $2,123
Food & beverage: $2,072Education: $51
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $691 |
| Janssen Biotech, Inc. | 11 | $364 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $265 |
| Madrigal Pharmaceuticals | 5 | $251 |
| Aimmune Therapeutics, Inc. | 4 | $118 |
| Amgen Inc. | 1 | $76 |
| Lilly USA, LLC | 3 | $57 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $57 |
| PFIZER INC. | 3 | $57 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
Products named: TREMFYA, SKYRIZI, REZDIFFRA, ENTYVIO, RINVOQ, ZENPEP, EVENITY, LINZESS.
Industry payments across FL — which companies pay providers there.
